Introduction: The advances and studies carried out in the area have shown that patients with aortic stenosis (AS) undergoing surgical valve replacement (SAVR) did not have encouraging outcomes. This study aims to compare the different risk factors in patients with AS undergoing transcatheter aortic valve replacement (TAVR) vs. SAVR, respectively, to offer options and more favorable results based on the results obtained in patients with these conditions. Methods: The study was in accordance with the PRISMA guidelines. Studies comparing outcomes of surgical and transaortic catheter valve replacements in adults were included. Descriptive statistics, binary random effects, and continuous random effects were used. I ² statistics were used to assess for heterogeneity. A P -value ≤0.05 was considered statistically significant. Results: In total, eight studies with 18 671 patients were included in our study. All-cause mortality (2.48% vs. 3.03%), major bleeding (11.25% vs. 31.05%), and atrial fibrillation (2.39% vs. 50.42%) were lower in TAVR compared to SAVR. Furthermore, odds of all-cause mortality (odds ratio [OR]: 0.79; 95% CI: 0.63–1.00; P = 0.05), stroke (OR: 0.71; 95% CI: 0.58–0.87; P = 0.0008), and acute kidney injury (AKI) (OR: 0.38; 95% CI: 0.29–0.49; P < 0.00001) were lower in the TAVR group compared to the SAVR group. Conclusion: TAVR is superior to SAVR and significantly reduces the risks associated with all-cause mortality, stroke, AKI, and other clinical outcomes. Furthermore, additional research is regarding the long-term effects of transcatheter aortic valve replacement.

Background: Albumin acts as a scavenger of reactive oxygen species and an inhibitor of inflammatory processes that underlie hepatic encephalopathy (HE). However, the role of albumin in hepatic encephalopathy is not well-established. The authors performed this meta-analysis to evaluate the efficacy and safety of albumin in the management of hepatic encephalopathy. Methods: The authors carried out an extensive search across multiple databases, including MEDLINE (via PubMed), Embase, CENTRAL, and various trial registries, to identify randomized controlled trials (RCTs) evaluating the impact of albumin administration in HE. The authors used a random-effects model for analyses and presented dichotomous outcomes and continuous outcomes as relative risk and mean difference, along with corresponding 95% CIs, respectively. Heterogeneity was assessed using both the I² index and χ² test. Results: Our meta-analysis included 4 RCTs involving 306 patients. Our primary outcomes, mortality, and persistence of HE were reported by all four studies. Albumin was found to significantly decrease mortality in patients with HE [risk ratio (RR) 0.52, 95% CI 0.32–0.83; I2 =0%]. Persistence of HE was found to be comparable between the two groups (RR 0.83, 95% CI 0.68–1.00; I2 =24%). There was no significant difference between the albumin and control groups regarding length of hospital stay (MD −1.55, 95% CI −3.5 to 0.14; I2 =41%), adverse events (RR 1.00, 95% CI 0.87–1.16; I2 =0%), and severe adverse events (RR 0.89, 95% CI 0.59–1.35). Conclusion: Albumin administration in patients with hepatic encephalopathy decreases mortality but does not significantly impact the persistence of HE. Further high-quality, large-scale randomized controlled trials are needed to provide conclusive evidence.

Objectives: A minimally invasive approach by a right mini-thoracotomy has been developed for surgical ablation of atrial fibrillation. However, the efficacy and safety compared to a median sternotomy remains unclear. Methods: We searched PubMed, Embase, and the Cochrane Library for eligible studies. Meta-analysis was performed for primary (recurrence of atrial tachyarrhythmias at 1 and 2 years) and secondary (hospital and ICU stay, adverse events, 30-day mortality, cardiopulmonary bypass, and aortic cross-clamp time) end-points. We compared end-points using risk ratio (RR) for binary outcomes and mean difference (MD) for continuous ones. We calculated 95% confidence intervals (CI) and used the random-effects model for all outcomes. We performed subgroup analysis for the main outcome based on lesion set, energy source, type of surgery, and propensity score matching. Results: We included 12 observational studies (n = 3122). No difference was found for the primary outcome at 1 (RR 0.8; [95% CI]: 0.62-1.03; P = 0.08) and 2 years (RR 0.9; [95% CI]: 0.74-1.13; P = 0.4). The thoracotomy group had lower complications (RR 0.72; [95% CI]: 0.55-0.97; P = 0.016), 30-day mortality (OR 0.26; [95% CI]: 0.10-0.70; P = 0.007), hospital stay (MD −5.35; [95% CI]: −7.94 to 2.77; P < 0.001), and ICU stay (MD −2.21; [95% CI]: −3.02 to 1.40; P < 0.001). Cardiopulmonary bypass and aortic clamping time were significantly higher in the thoracotomy group. Conclusions: This meta-analysis found that surgical ablation by a mini-thoracotomy might achieve similar rhythm control to a median sternotomy while possibly improving safety and promoting faster recovery. However, conclusions are limited by the observational nature of the evidence and randomized trials are warranted.

Background: Anterior cervical discectomy and fusion (ACDF) is a common treatment for cervical radiculopathy and myelopathy. While generally effective, diabetes mellitus may increase postoperative complications and healthcare costs. This study evaluated the impact of type 2 diabetes on perioperative outcomes in ACDF patients. Methods: A retrospective cohort study was conducted using the Nationwide Inpatient Sample (2016–2019), including 85,585 single-level ACDF patients. Propensity score matching (PSM) was applied, creating two balanced cohorts (16,260 diabetic and 16,260 non-diabetic patients). Outcomes analyzed included postoperative complications, length of stay, hospital charges, and mortality. Results: Diabetic patients had significantly higher risks of ACDF-specific complications, including cerebrospinal fluid leaks (2×), dysphagia (2.5×), dysphonia (2.9×), and cervical spinal cord injury (5×). General complications were also increased, with higher rates of pulmonary embolism (2.4×), sepsis (3×), stroke (3×), pneumonia (3.3×), and heart failure (12×). Diabetic patients had longer hospital stays (1.99 vs. 1.79 days, p < 0.001) and higher hospital charges (USD 71,884 vs. USD 67,998, p = 0.004). Conclusions: T2DM significantly increases postoperative risks, length of stay, and costs for ACDF patients. Optimized perioperative management and glucose control are essential to improve outcomes in this high-risk population.